

## Correction

---

PH Tan, AA Thike, WJ Tan *et al.* Predicting clinical behaviour of breast phyllodes tumours: a nomogram based on histological criteria and surgical margins. *J Clin Pathol* 2012;65:69–76. There are errors in Tables 1, 8 and 9 of this paper, the following information has been corrected. In Table 1 under ‘Clinicopathological features’, Size (mm) (mean 52, median 40, range 3–250) has been changed to: Size (mm) (mean 52, median 40, range 8–250). In Table 8 under ‘Factor’, the second entry of Grade has been deleted. The following text has been removed from the footnote: ‘It should be noted that the nomogram has a score range between 0 and 100, but the total histological score has a more limited range between 5 and 13, accounting for the apparently higher HR.’ The table footnote now reads: HR (hazard ratio) refers to recurrence risk relative to reference. hpf, high-power fields; NR, not reached; PASH, pseudoangiomatous stromal hyperplasia. In Table 9, the following text has been removed from the footnote: It should be noted that the nomogram has a score range between 0 and 100, but the total histological score has a more limited range between 5 and 13, accounting for the apparently higher HR. The footnote now reads: HR (hazard ratio) refers to recurrence risk relative to reference. hpf, high-power fields; NR, not reached.

*J Clin Pathol* 2013;66:455–456. doi:10.1136/jclinpath-2011-200368corr1

**Table 1** Clinicopathological features of 605 cases of phyllodes tumour stratified according to histological grade

Clinicopathological features	Benign	Borderline	Malignant	p Value
Age (years) (mean 42, median 43, range 15–79)				<0.001
<mean age	227 (37.5%)	36 (5.9%)	16 (2.6%)	
≥mean age	213 (35.2%)	75 (12.5%)	38 (6.3%)	
Ethnicity				0.724
Chinese	307 (50.7%)	81 (13.4%)	37 (6.1%)	
Malay	66 (11.2%)	19 (3.1%)	10 (1.6%)	
Indian	31 (5.1%)	3 (0.5%)	0 (0%)	
Others	36 (5.9%)	8 (1.3%)	7 (1.1%)	
Size (mm) (mean 52, median 40, range 8–250)				<0.001
<mean size	343 (56.7%)	54 (8.9%)	16 (2.6%)	
≥mean size	97 (16.1%)	57 (9.4%)	38 (6.3%)	
Microscopic borders				<0.001
Circumscribed	283 (46.8%)	49 (8.1%)	20 (3.3%)	
Permeative	157 (26.0%)	62 (10.2%)	34 (5.6%)	
Stromal hypercellularity				<0.001
Mild	302 (49.9%)	21 (3.5%)	3 (0.5%)	
Moderate	131 (21.7%)	75 (12.4%)	25 (4.1%)	
Marked	7 (1.1%)	15 (2.5%)	26 (4.3%)	
Stromal atypia				<0.001
Mild	412 (68.1%)	54 (8.9%)	0 (0%)	
Moderate	28 (4.8%)	54 (8.9%)	30 (4.9%)	
Marked	0 (0%)	3 (0.5%)	24 (3.9%)	
Stromal overgrowth				<0.001
Absent	440 (72.8%)	86 (14.2%)	14 (2.3%)	
Present	0 (0%)	25 (4.1%)	40 (6.6%)	
Mitotic activity/10 hpf				<0.001
0–4	402 (66.4%)	31 (5.1%)	5 (0.8%)	
5–9	34 (5.6%)	51 (8.4%)	15 (2.5%)	
≥10	4 (0.7%)	29 (4.9%)	34 (5.6%)	
Surgical margins				0.511
Complete (Not involved)	257 (42.5%)	58 (9.6%)	34 (5.6%)	
Focal involvement	168 (27.7%)	44 (7.3%)	16 (2.6%)	
Diffuse involvement	15 (2.5%)	9 (1.5%)	4 (0.7%)	

hpf, high-power fields.

**Table 9** Multivariate analysis of recurrence-free survival without interaction

Factor	No. of patients	No. of events	Median survival (months)	HR (95% CI)	p Value
Mitoses per 10 hpf	552	82	NR	1.03 (1.00 to 1.06)	<b>0.0580</b>
Surgical margin					
Negative	314	15		Reference	
Positive	238	67		8.37 (4.71 to 14.90)	<b>&lt;0.0001</b>
Atypia					
Mild	424	48	NR	Reference	
Moderate	101	23	NR	1.79 (1.01 to 3.16)	<b>0.0446</b>
Marked	27	11	NR	3.28 (1.48 to 7.23)	<b>0.0033</b>
Overgrowth					
Absent	482	63	NR	Reference	
Present	70	19	NR	2.28 (1.19 to 4.36)	<b>0.0126</b>
Hypercellularity					
Mild	302	31	NR	Reference	
Moderate	208	41	NR	1.21 (0.71 to 2.06)	0.4786
Marked	42	10	NR	0.47 (0.17 to 1.31)	0.1496

HR (hazard ratio) refers to recurrence risk relative to reference.

hpf, high-power fields; NR, not reached.

**Table 8** Univariate analysis of recurrence free survival of women with PT

Factor	No of patients	No of events	Median survival (months)	HR* (95% CI)	p Value
All	552	85	NR		
Age	552	85	NR	1.00 (0.98 to 1.02)	0.7006
Size	552	85	NR	1.00 (1.00 to 1.01)	0.1725
Grade					<b>&lt;0.0001</b>
Benign	399	46	NR	Reference	
Borderline	103	17	NR	1.67 (0.96 to 2.92)	
Malignant	50	19	NR	3.83 (2.24 to 6.53)	
Mitoses per 10 hpf	552	85	NR	1.05 (1.03 to 1.07)	<b>&lt;0.0001</b>
Surgical margin					<b>&lt;0.0001</b>
Negative	314	15	NR	Reference	
Positive	228	70	NR	7.14 (4.07 to 12.52)	
Type of surgery					0.0593
Excision	375	57	NR	Reference	
Mastectomy	62	15	NR	1.72 (0.98 to 3.04)	
Wide excision	114	10	NR	0.60 (0.31 to 1.17)	
Core biopsy	1	0	NR	—	
Race					0.2095
Chinese	394	60	NR	Reference	
Malay	89	17	NR	1.29 (0.75 to 2.22)	
Indian	34	1	NR	0.19 (0.03 to 1.39)	
Others	35	4	NR	1.04 (0.38 to 2.87)	
Atypia					<b>&lt;0.0001</b>
Mild	424	48	NR	Reference	
Moderate	101	23	NR	2.16 (1.316 to 3.55)	
Marked	27	11	NR	4.42 (2.29 to 8.50)	
Hypercellularity					<b>0.0005</b>
Mild	302	31	NR	Reference	
Moderate	208	41	NR	2.22 (1.39 to 3.54)	
Marked	42	10	NR	2.83 (1.39 to 5.78)	
Overgrowth					<b>0.0003</b>
Absent	482	63	NR	Reference	
Present	70	19	NR	2.49 (1.49 to 4.15)	
Borders					<b>0.0047</b>
Circumscribed	314	33	NR	Reference	
Permeative	238	49	NR	1.87 (1.20 to 2.91)	
PASH					0.3569
Absent	329	47	NR	Reference	
Present	222	34	NR	0.81 (0.52 to 1.27)	

HR (hazard ratio) refers to recurrence risk relative to reference.

hpf, high-power fields; NR, not reached; PASH, pseudoangiomatous stromal hyperplasia.